1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

AbbVie Maintains US Humira Erosion Belief As 2023 Negotiations Near

Originator Has Previously Outlined 45% Erosion ‘Plus-Or-Minus 10%’

 
• By Dean Rudge

AbbVie is not yet changing its modelling for Humira’s erosion in 2023, when as many as nine competing biosimilars could launch. The originator stated however that it will be in a better position to comment when it “goes through negotiations this summer” with payers and insurance providers.

Alarm clock dollar bills money
Evercore: Humira is in a strong formulary position • Source: Alexander Sánchez / Alamy Stock Photo

AbbVie Inc. says it will be in a better position to refine the first-year expected erosion rate for its $14bn Humira (adalimumab) brand in the US “later this year,” amid negotiations for formulary access, as the clock ticks ever closer to the first biosimilar launch in January 2023.

Currently, the US-based originator is sticking with its past guidance of 45% erosion in 2023 – when as many as nine biosimilar adalimumab products may

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

 
• By Urtė Fultinavičiūtė

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”